Research And Views Archives | Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks


Login Failure
(Please do not use this option on a public machine)
  Sign Up | Forgot Password?  

Archives... Don't Miss Anything, Ever!

Here you will find all the research and views that we post on Equitymaster. Use the tools to customize the results to suit your preference!


Apollo Hospitals: No clear signs

Feb 21, 2003

Apollo Hospitals Enterprises Limited (AHEL), the largest hospital chain in the country has announced encouraging December quarter results. The company has reported a robust 24% topline growth in 3QFY03 while the bottomline growth has been limited to 11%. Bottomline growth has been aided by an improvement in margins.

Will generics provide the answer for Indian pharma companies?

Apr 19, 2000

A lot is being made out about the Indian pharmaceutical companies abilities to tap the US generic market post 2003 with almost 36 blockbuster drugs going off patent. The market is estimated to be worth around $ 32 bn almost five times the size of the domestic market. There have been articles and editorials recently to the effect that the Indian pharma companies have come of age. We seek to put things in perspective.

Ranbaxy serves strong dose in anti–diabetes market

Apr 4, 2000

Eli Lilly Ranbaxy, the joint venture between Ranbaxy and the US based Eli Lilly have introduced a reusable insulin delivery device. This product would provide the users of Himinsulin (Eli Lilly’s product) a convenient way of injecting insulin.

Wockhardt heralds corporatisation of medical services

Mar 31, 2000

Wockhardt Life Sciences has taken administrative charge of the Maharashtra government owned GT Hospitals.

Pharma valuations: a skewed medicine

Mar 28, 2000

Would you believe that the market capitalisation of Ranbaxy is more than the combined market capitalisation of Glaxo, Pfizer, SmithKline Pharma, Hoechst Marion Roussel, Burroughs Wellcome, E Merck, German Remedies, Knoll Pharma, Fulford and Abbott Laboratories put together?

Pfizer targets SmithKline with Shanta’s Hep B vaccine

Mar 24, 2000

Pfizer India has entered into a co–marketing tie up with Shanta Biotech to market the latter Hepatitis B vaccine under the brand name Hepashield. Shanta Biotech markets the vaccine under the brand name ‘Shanvac’.

Competition hots up in Hep–B vaccine segment

Mar 14, 2000

Wockhardt has launched a Hepatitis B vaccine Biovac B. This is in collaboration with a German company Rhein Biotech GmbH.

Interest cost on Merind takeover pulls down Wockhardt net

Feb 29, 2000

Wockhardt has declared impressive operations results for the 18-month period ended December 1999. The company extended its year to 18 months primarily since it has changed its year ending from June to December as well as de-merged its non-pharmaceutical businesses into a separate company – Wockhardt Life Sciences. The current results include the performance of the non-pharma business too.

Nicholas Piramal to sell of Deonar plant

Feb 16, 2000

Nicholas Piramal (NPIL) is planning to sell its Deonar facility. The company plans to offer a Voluntary Retirement Scheme to its existing staff of around 180 people.

Wockhardt to takeover US partner Sidmak Labs

Jan 24, 2000

Wockhardt is in advanced talks to acquire majority control in Sidmak Laboratories Inc for around $100 m. Sidmak is among the top 10 generic companies with a basket of almost 100 products.

Dr. Reddy’s wins patent row with Merck in Russia

Jan 21, 2000

A Russian arbitration court has ruled in favour of the Dr. Reddy’s Laboratories (DRL) in a patent row with the American Merck & Co.

Core Healthcare to settle dues via sale of assets

Jan 13, 2000

Core Healthcare is set to finance the settlement of its dues with 20 creditors through a sale of large chunks of its assets. The Rs 3.2 billion company owes its creditors almost Rs 10 billion.

Orchid takes over Ajanta bulk drug plant

Jan 5, 2000

Orchid Chemicals is acquiring the bulk drug facility of Ajanta Pharmaceuticals. The price tag that the company is to pay for the Aurangabad based plant has been fixed at Rs 210 m.

Nicholas Piramal acquires four brands

Dec 25, 1999

Nicholas Piramal has acquired India rights for three anti-infective and one anti-viral brand from the Eli Lilly Ranbaxy joint venture. The three anti-infective brands, Mucokef, Zidime and Keroxime belong to Eli Lilly while the anti-viral brand Lovir belongs to Ranbaxy. The deal is expected to have cost Rs 100 m.

Strong dose from Dr. Reddy’s

Dec 14, 1999

Cheminor Drugs (Cheminor) part of the Dr. Reddy’s group is likely to assume full control of its US venture Reddy Cheminor Inc by acquiring the 25% holding of its US partner.

Dr Reddy's, American Remedies in wedlock

Nov 27, 1999

According to newspaper reports, Dr Reddy's Laboratories (DRL) has acquired a 45% stake in American Remedies (ARL). The deal has been clinched with the promoters at Rs 175 per share. The deal has been termed as the largest and most significant pharmaceutical deal in 1999.

Drug price control list may be pruned

Nov 16, 1999

According to newspaper reports, the Drug Price Review Committee (DPRC) has recommended that the number of drugs under price control should be pruned to 55 from the present 74 and the price control turnover criteria for bulk drugs be more than doubles to Rs 100 m.

Dr Reddy's Russian woes take a new turn

Nov 15, 1999

The introduction of product patents in India may be still sometime away but other countries such as Russia are paying more heed to the World Trade Organisation rulings. Pfizer, it has been reported, has successfully sued Dr Reddy's for selling a heart ailment product, which is similar to its own product in Russia. The Indian company has claimed that the product has been manufactured by an entirely different process.

Kopran net profit up marginally in 2QFY2000

Nov 1, 1999

Pharmaceutical company Kopran Limited net profit surged by a marginal 2% to Rs 42 m in its second quarter ended September 30, 1999. Turnover declined by a shade to Rs 510 m during the same period.

Ranbaxy targets US$ 1 bn global sales

Oct 29, 1999

Ranbaxy Laboratories is targeting global sales of US$ 1 bn by the year 2004. This was revealed by company sources at an analyst meet.

India's #1 Trader
Reveals His Secrets

Secret To Increasing Your Trading Profits Today
Get our special report, Secret to Increasing Your Trading Profits Today Now!
We will never sell or rent your email id.
Please read our Terms